In a January 31, 2022 letter to Drew Hirshfeld, the Commissioner for Patents for the USPTO, and Janet Woodcock, the Acting Commissioner of the FDA, Senator Thom Tillis provides extensive criticism of the empirical work of the group I-MAK and the data from the University of California, Hastings College of the Law Evergreen Drug Patent Database.
Sen. Tillis’ letter available here: SenatorTillis2FDAandUSPTO31jan2022.pdf
Interestingly, in the letter Sen. Tillis, the ranking GOP member in the Senate Judiciary Committee’s Subcommittee on Intellectual Property, asks the FDA and the USPTO to conduct a study to present to Congress by December 31, 2022, to provide an “assessment and analysis of the sources and data that are being relied upon by those advocating for patent-based solutions to drug pricing”.